Vasculotide Peptide Targets Tie2 Receptor to Reduce Allergic Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for allergic diseases, particularly those involving eosinophils and basophils, often lead to general immunosuppression and do not effectively address the underlying inflammatory responses, with existing therapies failing to specifically target these cells for reduction.
Innovation Solution
Administration of a multimeric Tie2 binding peptide, Vasculotide, which inhibits the expansion of granulocyte colony-forming units (CFU-G), thereby reducing eosinophils and basophils, using a method that specifically targets the Tie2 receptor to treat allergic diseases without causing general immunosuppression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If current treatments for allergic diseases are used, then eosinophils and basophils are reduced, but general immunosuppression occurs
Solution Approach 1:
The patent applies local quality by using a Tie2-specific peptide agonist that selectively targets the Tie2 receptor on hematopoietic progenitor cells to reduce eosinophils and basophils. This localized action at the Tie2 receptor level allows reduction of specific allergic inflammatory cells without causing general immunosuppression, as the peptide acts specifically on Tie2-expressing cells rather than broadly suppressing the immune system.
2Quantity of substance
If general immunosuppression is used to treat allergic diseases, then eosinophils and basophils are reduced, but the underlying inflammatory responses are not addressed
Solution Approach 1:
The patent extracts the specific mechanism of Tie2 receptor activation from general immunosuppression. By using a peptide agonist that specifically binds to and activates Tie2, the invention isolates and targets the specific pathway responsible for eosinophil and basophil production. This extraction allows precise reduction of these cells through Tie2 activation without the broad, non-specific effects of general immunosuppression.
3Quantity of substance
If existing therapies are used, then eosinophils and basophils are reduced, but side effects increase
Solution Approach 1:
The patent changes the parameter of target specificity by shifting from non-specific immunosuppression to Tie2 receptor-specific activation. The peptide agonist is designed to bind with high affinity to Tie2, changing the interaction parameter from broad immune suppression to targeted receptor activation. This parameter change reduces side effects by limiting the therapeutic action to Tie2-expressing hematopoietic progenitor cells.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Vasculotide effectively reduces eosinophils and basophils, ameliorating conditions such as atopic dermatitis and asthma by specifically targeting the Tie2 receptor, thereby minimizing side effects and improving disease outcomes without general immunosuppression.
Implementation Method 1
when configured as a tetramer results in the clustering of the receptor and its activation
Implementation Method 2
activate Tie2 receptor tyrosine kinase activity
Implementation Method 3
inhibit the expansion of CFU-G cells, resulting in a reduction in eosinophils and basophils
Data Source
AI summary
The present disclosure provides methods and uses of Tie2 binding and/or activating agents. In particular, the present disclosure provides methods and uses for inhibiting the expansion of colony forming unit-granulocytes, reducing eosinophils and/or basophils, for treating allergic disease or response or eosinophil/basophil associated condition and for reducing inflammatory cytokine and/or chemokine levels.